About Us
Established in 2019, Innervate Radiopharmaceuticals (IRP) is developing a late-stage Positron Emission Tomography (PET) Imaging radiopharmaceutical.
We are currently testing our leading asset, 18F- metafluorobenzylguanidine (mFBG), a novel PET imaging biomarker. PET imaging has significant advantages over Single Photon Emission Computed Tomography (SPECT), the current standard of care for biomarker imaging in neuroblastoma patients.
Compared with approved SPECT agents, PET produces higher-resolution images and frequently identifies otherwise undetected lesions. We hope to show through our clinical trials that PET imaging with mFBG will provide more accurate and reliable information on the extent of the disease and, in turn, lead to important improvements in patient management and outcomes for patients with neuroblastoma and potentially other diseases.
IRP is currently conducting a pivotal Phase-III study in neuroblastoma patients with suspected or a previous diagnosis of Neuroblastoma. IRP has received Rare Pediatric and Orphan Disease designations from the FDA to develop mFBG.
IRP’s open-label, multi-center Phase-III study is being conducted at several locations in the NANT consortium, at Memorial Sloan Kettering Cancer Center in New York and Riley Children’s Hospital in Indianapolis.
A brief description of the study and a list of participating institutions can be found at:
Additionally, IRP is conducting a Phase-I/IIa Cardiovascular study designed to evaluate the capabilities of mFBG in imaging Myocardial Sympathetic Innervation.
This single-center study is being conducted at Mount Sinai Medical Center in New York City. It is led by Dr. Jagat Narula.
Scott Korman
Chief Executive Officer
Founded (1984) Nashone, Inc., a private equity investment and advisory firm.
Broad ranging C-suite responsibilities within various Nashone portfolio companies.
Extensive experience leading M&A transactions and corporate turnarounds.
Served on numerous public / private BOD.
Successfully oversaw reorg of $100M+ biotech / diagnostic company.
Thomas H. Tulip, Ph.D.
Chief Science Officer
Healthcare executive with more than 25 years of medical imaging industry experience.
Recognized medical imaging leader, Executive Board Member of the Medical Imaging Technology Associate (MITA) and former Director of the Academy of Molecular Imaging, and Chairperson of the Institute for Molecular Technologies.
Former Executive at Navidea, Alseres, Lantheus, and Bristol-Myers Squibb
Instrumental in the development and commercialization of Cardiolite®.
David Turner
Chief Operating Officer
Founded (2015) Simon Venture Partners, LLC, a Business Development and Financial Advisory firm.
20+ year finance veteran of JP Morgan (18), Lehman Brothers (2), and Macquarie Bank (3).
Extensive experience in, equity finance, derivatives, structured products, capital markets, IPO and follow-on financings.
Worked regularly with top tier global pharma on international financings.
Managed research sales and trading divisions domestically and internationally.
Helped international companies successfully navigate FDA applications and approvals.
Arnold Jacobson MD, Ph.D.
Chief Medical Officer
Medical professional with more than 30 years of nuclear medicine, radiology, and radiological physics experience.
Radiopharmaceutical industry veteran with years of experience at Amersham Health & GE Healthcare.
Previous academic appointments at Harvard Medical School, the University of Washington ,and the Icahn School of Medicine at Mount Sinai.
Stephen Haber, Ph.D.
Senior Drug Development Advisor
Senior executive with 40+ years in the pharmaceutical / radiopharmaceutical industry.
Former Vice President of Drug Development for Navidea Biopharmaceuticals, as well as a former senior executive at Lantheus Medical Imaging.
Founder of Haber Life Science Consulting, providing advisory services related to radiopharmaceutical drug development, manufacturing and clinical trial design.
Austin Lewis
Founding Board Member
Founder and General Partner of Lewis Opportunity Fund - 17 years.
Seasoned Investor and Board Member of multiple private and public early-stage companies.
Successful record of finding, seeding and scaling young companies.
Scott Korman
Chief Executive Officer
Founded (1984) Nashone, Inc., a private equity investment and advisory firm.
Broad ranging C-suite responsibilities within various Nashone portfolio companies.
Extensive experience leading M&A transactions and corporate turnarounds.
Served on numerous public / private BOD.
Successfully oversaw reorg of $100M+ biotech / diagnostic company.
Thomas H. Tulip, Ph.D.
Chief Science Officer
Healthcare executive with over than 25 years medical imaging industry experience
Recognized medical imaging leader, Executive Board Member of the Medical Imaging Technology Associate (MITA) and former Director of the Academy of Molecular Imaging, and Chairperson of the Institute for Molecular Technologies.
Former Executive at Navidea, Alseres, Lantheus, and Bristol-Myers Squibb.
Instrumental in the development and commercialization of Cardiolite®.
David Turner
Chief Operating Officer
Founded (2015) Simon Venture Partners, LLC, a Business Development and Financial Advisory firm.
20+ year finance veteran of JP Morgan (18), Lehman Brothers (2), and Macquarie Bank (3).
Extensive experience in, equity finance, derivatives, structured products, capital markets, IPO and follow-on financings.
Worked regularly with top tier global pharma on international financings.
Managed research sales and trading divisions domestically and internationally.
Helped international companies successfully navigate FDA applications and approvals.
Arnold Jacobson MD, Ph.D.
Chief Medical Officer
Medical professional with more than 30 years nuclear medicine, radiology and radiological physics experience
Radiopharmaceutical industry veteran with nearly 20 years’ experience at Amersham Health & GE Healthcare
Previous academic appointments at Harvard Medical School, the University of Washington, and the Icahn School of Medicine at Mount Sinai.
Stephen Haber, Ph.D.
Senior Drug Development Advisor
Senior executive with 40+years pharmaceutical / radiopharmaceutical industry
Former Vice President of Drug Development for Navidea Biopharmaceuticals as well as former senior executive at Lantheus Medical Imaging
Founder of Haber Life Science Consulting, providing advisory services related radiopharmaceutical drug development, manufacturing and clinical trial design.
Austin Lewis
Founder Board Member
Founder and General Partner of Lewis Opportunity Fund - 17 years.
Seasoned Investor and Board Member of multiple private and public early stage companies.
Successful record of finding, seeding and scaling young companies.